Please ensure Javascript is enabled for purposes of website accessibility

NPS Pharmaceuticals' Q4 Revenue Doubles as It Reverses a Year-Ago Loss

By Sean Williams – Feb 18, 2014 at 6:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Strong sales of Gattex combined with a 44% increase in royalty revenue drive NPS' top- and bottom-lines significantly higher.

NPS Pharmaceuticals (NASDAQ: NPSP) continued to live up its too hot to handle reputation in the after-hours this evening after the biopharmaceutical company reported robust sales and bottom-line growth with its fourth-quarter results.

For the quarter, NPS' revenue jumped 101% to $54.5 million from $27.2 million in the year-ago period. This jump includes a 44% jump in its royalty revenue to $39.2 million – of which a majority came from the sale of Amgen's (AMGN 1.56%) Sensipar which provided $36.4 million of its $39.2 million in royalty revenue – as well as $15.3 million in product revenue from short bowel syndrome drug, Gattex (known as Revestive in the EU). NPS did not recognize any product revenue during the fourth-quarter last year.

According to its report, 303 patients were taking Gattex as of the end of the quarter, in line with the company's prior guidance of 275 to 325 patients. NPS further states that it anticipates "recognizing meaningful commercial sales from ex-US territories in the second-half of 2014."

In addition to robust top-line growth, NPS reversed a $12.2 million net loss, or an adjusted $0.14 per share from last year, by reporting net income of $7.8 million, or $0.07 per share in the fourth-quarter. The company also finished the year with $180 million in cash and marketable investment securities compared to just $101 million in the year prior.

Looking ahead, NPS is forecasting net Gattex/Revestive sales of $110 million-$120 million in 2014, representing 262% year-over-year growth at the midpoint, with operating expenses of $180 million-$200 million, an increase of 24% from fiscal 2014. NPS notes the increased expenses will go toward building up a pre-launch inventory for experimental hypoparathyroidism drug Natpara, trials related to expanding Gattex/Revestive to pediatric patients, and regulatory activities which include preparations for an FDA advisory committee meeting for Natpara. 

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Stock Quote
$286.40 (1.56%) $4.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.